Johnson & Johnson Website

Johnson & Johnson

NYSE-JNJ

Basic

  • Market Cap

    $353.71B

  • EV

    $361.12B

  • Shares Out

    2,406.68M

  • Revenue

    $85.65B

  • Employees

    131,900

Margins

  • Gross

    69.34%

  • EBITDA

    35.74%

  • Operating

    27.53%

  • Pre-Tax

    23.42%

  • Net

    44.92%

  • FCF

    21.29%

Returns (5Yr Avg)

  • ROA

    11.42%

  • ROTA

    98.5%

  • ROE

    28.79%

  • ROCE

    17.52%

  • ROIC

    16.15%

Valuation (TTM)

  • P/E

  • P/B

  • EV/Sales

  • EV/EBITDA

  • P/FCF

  • EV/Gross Profit

Valuation (NTM)

  • Price Target

    $172.51

  • P/E

  • PEG

  • EV/Sales

  • EV/EBITDA

  • P/FCF

Financial Health

  • Cash

    $26.22B

  • Net Debt

    $7,414M

  • Debt/Equity

    0.48

  • EBIT/Interest

    32.97

Growth (CAGR)

  • Rev 3Yr

    0.56%

  • Rev 5Yr

    0.97%

  • Rev 10Yr

    1.79%

  • Dil EPS 3Yr

    39.26%

  • Dil EPS 5Yr

    23.14%

  • Dil EPS 10Yr

    11.33%

  • Rev Fwd 2Yr

    3.24%

  • EBITDA Fwd 2Yr

    4.29%

  • EPS Fwd 2Yr

    5.12%

  • EPS LT Growth Est

    4.14%

Dividends

  • Yield

  • Payout

    69.26%

  • DPS

    $4.76

  • DPS Growth 3Yr

    5.62%

  • DPS Growth 5Yr

    5.75%

  • DPS Growth 10Yr

    6.07%

  • DPS Growth Fwd 2Yr

    3.53%

Select a metric from the list below to chart it

Dec '14

Jan '16

Jan '17

Dec '17

Dec '18

Dec '19

Jan '21

Jan '22

Jan '23

Dec '23

LTM

Dec '24 (E)

Dec '25 (E)

Dec '26 (E)

Total Revenues

82,059

82,584

78,740

79,990

85,159

85,648

Total Revenues % Chg.

0.6%

0.6%

-4.7%

1.6%

6.5%

10.6%

Cost of Goods Sold, Total

27,556

28,427

23,402

24,596

26,244

26,261

Gross Profit

54,503

54,157

55,338

55,394

58,915

59,387

Selling General & Admin Expenses, Total

21,885

21,731

19,506

19,078

20,166

20,640

R&D Expenses

11,355

12,159

14,277

14,135

15,085

15,172

Other Operating Expenses, Total

33,240

33,890

33,783

33,213

35,251

35,812

Operating Income

21,263

20,267

21,555

22,181

23,664

23,575

Interest Expense, Total

-318

-201

-183

-276

-772

-715

Interest And Investment Income

357

111

53

490

1,261

1,427

Net Interest Expenses

39

-90

-130

214

489

712

Currency Exchange Gains (Loss)

-267

-209

-216

-286

-366

-314

Other Non Operating Income (Expenses)

-3,909

-2,922

-550

1,744

1,664

1,632

EBT, Excl. Unusual Items

17,126

17,046

20,659

23,853

25,451

25,605

Restructuring Charges

-266

-247

-209

-275

-798

-839

Merger & Related Restructuring Charges

-300

-200

-300

Gain (Loss) On Sale Of Investments

300

1

-700

-600

-445

Gain (Loss) On Sale Of Assets

2,154

111

617

380

117

109

Asset Writedown

-1,096

-233

-989

-1,216

-1,295

-1,103

In Process R&D Expenses

-890

-181

-900

-783

-313

-264

Legal Settlements

-900

-6,900

-2,700

Other Unusual Items

-700

-400

EBT, Incl. Unusual Items

17,328

16,497

19,178

19,359

15,062

20,063

Income Tax Expense

2,209

1,783

1,377

2,989

1,736

2,991

Earnings From Continuing Operations

15,119

14,714

17,801

16,370

13,326

17,072

Earnings Of Discontinued Operations

3,077

1,571

21,827

21,404

Net Income

15,119

14,714

20,878

17,941

35,153

38,476

Net Income to Common Incl Extra Items

15,119

14,714

20,878

17,941

35,153

38,476

Net Income to Common Excl. Extra Items

15,119

14,714

17,801

16,370

13,326

17,072

Total Shares Outstanding

2,632.5

2,632.5

2,629

2,613.6

2,407.1

2,406.7

Weighted Avg. Shares Outstanding

2,645.1

2,632.8

2,632.1

2,625.2

2,533.5

2,484.2

Weighted Avg. Shares Outstanding Dil

2,684.3

2,670.7

2,674

2,663.9

2,560.4

2,516.6

EPS

5.7

5.6

7.9

6.8

13.9

15.5

EPS Diluted

5.6

5.5

7.8

6.7

13.7

15.3

EBITDA

28,272

27,498

28,206

28,510

30,767

30,613

Effective Tax Rate

12.7%

10.8%

7.2%

15.4%

11.5%

14.9%